相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer
Pamela R. Drullinsky et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
Nicci Owusu-Brackett et al.
Oncotarget (2020)
Are we ready to use TMB in breast cancer clinical practice?
Sara Ravaioli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Targeting the PI3-kinase pathway in triple-negative breast cancer
J. Pascual et al.
ANNALS OF ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms
Ik Sun Kim et al.
NATURE CELL BIOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O'Donnell et al.
SEMINARS IN CANCER BIOLOGY (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins et al.
NATURE (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
Jiqing Sai et al.
CLINICAL CANCER RESEARCH (2017)
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
Zev A. Wainberg et al.
TARGETED ONCOLOGY (2017)
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Trisha M. Wise-Draper et al.
TARGETED ONCOLOGY (2017)
Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich
CANCER IMMUNOLOGY RESEARCH (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Angel Guerrero-Zotano et al.
CANCER AND METASTASIS REVIEWS (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation
Thomas Welte et al.
NATURE CELL BIOLOGY (2016)
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Viktor Umansky et al.
VACCINES (2016)
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
Sarit Schwartz et al.
CANCER CELL (2015)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
E. M. Olson et al.
ANNALS OF ONCOLOGY (2012)
Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
Patrick J. Roberts et al.
CLINICAL CANCER RESEARCH (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Receptor Tyrosine Kinases and TLR/IL1 Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
Michael C. Schmid et al.
CANCER CELL (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ
Jennifer K. Uno et al.
GASTROENTEROLOGY (2010)
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER plus breast cancer
Chad J. Creighton et al.
BREAST CANCER RESEARCH (2010)
Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
Christina Gewinner et al.
CANCER CELL (2009)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
Fatima Cardoso et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
Neil E. Torbett et al.
BIOCHEMICAL JOURNAL (2008)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
分享论文
